

# Test Report

---

Report No.	WP-20064291-JC-01En
Sample Name	BEAUTY GLAZED Gorgeous Me EYE SHADOW TRAY
Sample Origin	Delivered from applicant
Client	DISRIBUTED BYJC(HK) INTERINTIONAL COSMETICS LTD

Shanghai Micro-spectial Chemical Analysis and Test technology Co.,Ltd.



# Test Report

Report No.: WP-20064291-JC-01En

Page No.: 1 / 7

Name of Sample	BEAUTY GLAZED Gorgeous Me EYE SHADOW TRAY		
Number	/	Specification	1.8g×63/box
Description of Sample	Powder	Lot No./Type	/
Client	DISRIBUTED BYJC(HK) INTERINTIONAL COSMETICS LTD		
Client Address	UNIT 2508A,BANK OF AMERICA TOWER 12 HARCOURT RD CENTRAL HK		
Sampling Date	/	Sample Receiving Date	2020-6-15
Test Date	2020-6-16~2020-6-19		
Test Item(s), Criterion(s) and Result(s)	Human patch test results show that, no adverse occurrence among 33.		
Note(s)	/		

Compiled by:

*Wenfeng Zhou*

Inspected by:

*Xiaojun Cai*

Approved by:

*Hong Shi*

Issued Date:

2020.6.19

# Test Report

Report No.: WP-20064291-JC-01En

Page No.: 2 / 7

## 1. Test Result(s):

Sample No.	Sample Name	Test Item	Test Result	Unit	Test Criterion	Remark
1	BEAUTY GLAZED Gorgeous Me EYE SHADOW TRAY	Human Patch Test <Safety and Technical Standards for Cosmetics,2015 edition>	Referring to the text	33	<Safety and Technical Standards for Cosmetics,2015 edition>	/

### Note(s): Material and Methodology

- 1.1 Investigational product: BEAUTY GLAZED Gorgeous Me EYE SHADOW TRAY prepared with olive oil into the 1:1 diluted solution
- 1.2 Negative Control (NC): Olive oil
- 1.3 Number of subjects: 33, onemen and thirty-two women, age:20 to 37 years old.

#### Inclusion criteria

- Volunteers aged 18-60 were selected as subjects.

#### Non-inclusion criteria

- Subject having a medical treatment or being vaccinated or expecting to be vaccinated during the study.
- Any anti-inflammatory drug applied to the subject site within the last two months.
- Subjects with inflammatory skin disease that has not been cured clinically.
- Insulin dependent diabetes.
- People who are being treated for asthma or other chronic respiratory problems.
- People received anticancer chemotherapy within the last 6 months.
- People with immune deficiency or autoimmune diseases.
- Subject pregnant, breastfeeding, or not willing to take necessary precautions to avoid a pregnancy during the study.
- Bilateral mastectomy and bilateral axillary lymph node resection.
- Subject not having respected the prohibition concerning the simultaneous acceptance of several biomedical research projects.
- Participate in other clinical trial investigators.
- Participated in other clinical trials within 2 months including the patch study investigator, or during the test recovery period.
- Highly sensitive.
- Non-volunteer participants or unable to complete the prescribed content according to the test requirements.

# Test Report

Report No.: WP-20064291-JC-01En

Page No.: 3 / 7

1.4 Test procedure: Select qualified patch, With the Occlusive patch test method, 0.020~0.025ml investigational product was put into the patch, and the product was removed 24 hours later. The skin reaction was observed 0.5, 24 and 48 hours after the removal. According to <Safety and Technical Standards for Cosmetics, 2015 edition> skin reaction grading standard for skin occlusive patch test

### Skin Reaction Grading Standard of Skin Occlusive Patch Test

Reaction Degree	Grade	Skin Reaction
-	0	Negative
±	1	Suspicious reaction with only weak erythema
+	2	Weak positive reaction (erythema reaction); Erythema, infiltration, edema, papules
++	3	Strong positive reaction (herpes reaction); Erythema, infiltration, edema, papules, herpes; The reaction can go beyond the test area
+++	4	Very Strong positive reaction (fusion herpes reaction); Obvious erythema, severe infiltration, edema, fusion herpes; Reaction beyond the test area

## Result

### Skin Patch Test Results of Cosmetic

Group	Number of Subjects	Observation Time	Number of Different Skin Reactions				
			0	1	2	3	4
<b>Investigational Product</b> BEAUTY GLAZED Gorgeous Me EYE SHADOW TRAY prepared with olive oil into the 1:1 diluted solution	33	0.5h	33	0	0	0	0
		24h	33	0	0	0	0
		48h	33	0	0	0	0
<b>NC</b> Olive oil	33	0.5h	33	0	0	0	0
		24h	33	0	0	0	0
		48h	33	0	0	0	0

**Human patch test results show that, no adverse occurrence among 33.**

\*\*\* End of the Page \*\*\*

# Test Report

Report No.: WP-20064291-JC-01En

Page No.: 4 / 7

## 2. Typical Attachment(s):

### Attachment Information A: Subject Information

No.	Name	Gender	Age	Fitzpatrick-Pathak Skin types	Whether statistical
1	GH	Female	24	III	YES
2	YF	Female	23	III	YES
3	HYL	Female	22	III	YES
4	ZL	Female	25	III	YES
5	ZN	Female	25	III	YES
6	LJY	Female	22	III	YES
7	DTT	Female	24	III	YES
8	HJ	Female	30	III	YES
9	QQW	Female	28	III	YES
10	ZKE	Female	25	III	YES
11	ZHW	Female	27	III	YES
12	WJK	Male	25	III	YES
13	WXC	Female	22	III	YES
14	MLL	Female	23	II	YES
15	SBW	Female	26	III	YES
16	WYQ	Female	29	III	YES
17	ZJ	Female	29	III	YES
18	GFF	Female	31	III	YES
19	ZX	Female	24	III	YES
20	TQ	Female	25	III	YES
21	ZYY	Female	20	III	YES
22	LLR	Female	33	III	YES
23	CM	Female	31	III	YES
24	ZY	Female	32	III	YES
25	HZH	Female	30	III	YES
26	SH	Female	36	III	YES
27	CCC	Female	37	III	YES
28	XBY	Female	36	III	YES
29	CYJ	Female	28	III	YES
30	LKJ	Female	30	III	YES
31	ZWF	Female	23	II	YES
32	ZRS	Female	22	II	YES

# Test Report

Report No.: WP-20064291-JC-01En

Page No.: 5 / 7

33	CXJ	Female	33	III	YES
----	-----	--------	----	-----	-----

Note: statistical reasons were not included: 1. Lost visit/late visit; 2. The tape falls off/the mark cannot be identified; 3. Negative control reaction

## Attachment Information B: Original Data

No.	Grade (0.5h)		Annotation (0.5h)	Grade (24h)		Annotation (24h)	Grade (48h)		Annotation (48h)
	S	NC		S	NC		S	NC	
1	0	0	None	0	0	None	0	0	None
2	0	0	None	0	0	None	0	0	None
3	0	0	None	0	0	None	0	0	None
4	0	0	None	0	0	None	0	0	None
5	0	0	None	0	0	None	0	0	None
6	0	0	None	0	0	None	0	0	None
7	0	0	None	0	0	None	0	0	None
8	0	0	None	0	0	None	0	0	None
9	0	0	None	0	0	None	0	0	None
10	0	0	None	0	0	None	0	0	None
11	0	0	None	0	0	None	0	0	None
12	0	0	None	0	0	None	0	0	None
13	0	0	None	0	0	None	0	0	None
14	0	0	None	0	0	None	0	0	None
15	0	0	None	0	0	None	0	0	None
16	0	0	None	0	0	None	0	0	None
17	0	0	None	0	0	None	0	0	None
18	0	0	None	0	0	None	0	0	None
19	0	0	None	0	0	None	0	0	None
20	0	0	None	0	0	None	0	0	None
21	0	0	None	0	0	None	0	0	None
22	0	0	None	0	0	None	0	0	None
23	0	0	None	0	0	None	0	0	None
24	0	0	None	0	0	None	0	0	None
25	0	0	None	0	0	None	0	0	None
26	0	0	None	0	0	None	0	0	None
27	0	0	None	0	0	None	0	0	None
28	0	0	None	0	0	None	0	0	None
29	0	0	None	0	0	None	0	0	None

# Test Report

Report No.: WP-20064291-JC-01En

Page No.: 6 / 7

30	0	0	None	0	0	None	0	0	None
31	0	0	None	0	0	None	0	0	None
32	0	0	None	0	0	None	0	0	None
33	0	0	None	0	0	None	0	0	None

\*\*\* End of the Page \*\*\*

# Test Report

Report No.: WP-20064291-JC-01En

Page No.: 7 / 7

### 3. Sample Picture(s):



\*\*\* End of the Report \*\*\*

### DECLARE:

- 1.The report is invalid without the stamp of special seal for test or without the signature of the compiler, the inspector and the approver.
- 2.No unauthorized changes, additions or deletions shall be made to the report.
- 3.Neither fragmented report nor its incomplete copy shall be deemed valid. The complete copy is invalid without the stamp of special seal for test.
- 4.Any queries on the report shall be presented to Shanghai Micro-spectral Chemical Analysis and Test technology Co.,Ltd. within 15 working days after receipt of the report.
5. The results described here in this report are based on the sample(s) tested. The results are presented to the client for internal uses only and do not constitute any social grounds in the People's Republic of China.
6. The client takes full responsible for the truthfulness of the testing sample(s) and information related thereto.